Akeso Inc. (4RY)

Overview

Akeso, Inc., headquartered in Zhongshan, the People's Republic of China, represents a cutting-edge biopharmaceutical entity dedicated to the creation, development, manufacturing, and global commercialization of novel antibody drugs. Founded in 2012, Akeso stands out in the competitive biopharmaceutical landscape through its commitment to groundbreaking research in antibody technologies. The company's diverse portfolio addresses a wide range of severe medical conditions, including various forms of cancer and autoimmune diseases, showcasing their dedication to improving patient outcomes across multiple therapeutic areas.

Products and Services

• AK104: A bi-specific antibody targeting PD-1/CTLA-4, designed to combat a variety of cancers such as cervical, gastric, lung, liver, and esophageal cancer. Its dual-target approach aims to enhance immune responses against tumor cells.
• AK112: Another bi-specific antibody, focusing on PD-1/VEGF, intended for the treatment of lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. By targeting both PD-1 and VEGF, AK112 seeks to inhibit tumor growth and evade immune suppression.
• AK117: A CD47 monoclonal antibody in development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma. Targeting CD47 can help to overcome the 'don't eat me' signal cancer cells use to avoid being ingested by macrophages.
• AK109: A PD-1 monoclonal antibody tailored for the treatment of G/GEJ (gastroesophageal junction) patients, focusing on enhancing the immune system's ability to recognize and destroy cancer cells.
• Penpulimab: A PD-1 targeting antibody for treating recurrent or metastatic nasopharyngeal carcinoma (NPC), aiming to improve immune system activity against tumor cells.
• Tagitanlimab: A PD-L1 inhibitor for the treatment of recurrent or metastatic NPC, designed to block the PD-L1 pathway, thereby restoring the immune system's ability to target cancer cells.
• AK102: A PCSK9 monoclonal antibody in development for treating hypercholesterolemia and mixed hyperlipidemia. By inhibiting PCSK9, AK102 helps to lower LDL cholesterol levels in the blood.
• AK101: An IL-12/IL-23 monoclonal antibody targeting moderate-to-severe psoriasis and ulcerative colitis. This antibody aims to modulate the immune response involved in these conditions.
• AK111: An IL-17 monoclonal antibody developed for treating moderate-to-severe psoriasis and ankylosing spondylitis, focusing on reducing inflammation and autoimmune responses.
• AK120: An IL-4R monoclonal antibody targeting moderate-to-severe atopic dermatitis. By inhibiting the IL-4R pathway, AK120 seeks to alleviate the symptoms of atopic dermatitis.